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Abstract: Clinical psychiatry is confronted with the expanding knowledge of medical genetics. 
Most of the research into the genetic underpinnings of major mental disorders as described in 
the categorical taxonomies, however, did reveal linkage with a variety of chromosomes. This 
heterogeneity of results is most probably due to the assumption that the nosological categories 
as used in these studies are disease entities with clear boundaries. If the reverse way of looking, 
the so-called bottom-up approach, is applied, it becomes clear that genetic abnormalities are 
in most cases not associated with a single psychiatric disorder but with a certain probability to 
develop a variety of aspeciﬁ  c psychiatric symptoms. The adequacy of the categorical taxonomy, 
the so-called top-down approach, seems to be inversely related to the amount of empirical 
etiological data. This is illustrated by four rather prevalent genetic syndromes, fragile X syn-
drome, Prader-Willi syndrome, 22q11 deletion syndrome, and Noonan syndrome, as well as 
by some cases with rare chromosomal abnormalities. From these examples, it becomes clear 
that psychotic symptoms as well as mood, anxiety, and autistic features can be found in a great 
variety of different genetic syndromes. A psychiatric phenotype exists, but comprises, apart 
from the chance to present several psychiatric symptoms, all elements from developmental, 
neurocognitive, and physical characteristics.
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Introduction
For psychiatry, both on the clinical and the scientiﬁ  c level, genetic disorders form 
a tremendous challenge since they present a unique opportunity to study psychiatric 
symptoms in relation to a known etiology and sometimes pathophysiology. Fur-
thermore, genetic abnormalities serve as impetus in the search for candidate genes 
for psychiatric syndromes (Muir et al 2006; Blackwood et al 2007). A comparable 
opportunity is presented by neurological disorders that are accompanied by psychiatric 
symptoms, like Parkinson’s disease, multiple sclerosis, and epilepsy (Verhoeven et al 
2006; Lyketsos et al 2007).
The categorical psychiatric taxonomies like the Diagnostic and Statistical Manual 
(DSM) of the American Psychiatric Association are in these cases routinely used for 
‘diagnosing’ psychiatric diseases, and often result in several diagnoses at the same 
time. This phenomenon is called comorbidity. As stated by van Praag (2000), the 
nosological way of thought carries with it harmful side effects such as proliferation 
of new diagnoses and magniﬁ  cation of comorbidity. In addition, current psychiatric 
diagnostics are based on the presumption that a common pathophysiology underlies 
psychiatric syndromes that were primarily tailored by consensus and not by empirical 
evidence. Thus, as in behavioral neurology, psychiatry should also operate from the 
bottom-up, ‘beginning with the emergence of pathology in the brain and attempting 
to understand the emerging of clinical syndromes out of this pathology’ (Lyketsos 
et al 2007). This ‘bottom-up’ approach also needs a theoretical framework because, Biologics: Targets & Therapy 2008:2(3) 410
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without theory, categories tend to increase as is illustrated by 
the growing number of the subsequent DSM-versions (Egger 
et al 2007). Clinical syndromes, out of such a ‘bottom-up’ 
orientation are not congruent with DSM categories but are 
reﬂ  ections of a certain probability to develop a variety of 
psychiatric and neurocognitive symptoms (Verhoeven et al 
2007, 2008).
The futility of the top-down approach is best illustrated 
by the ‘disorder’ called mental retardation that is not a dis-
ease or a disability but a ‘syndrome grouping that includes 
a heterogenous group of clinical conditions, ranging from 
genetic to nutritional, infectious, metabolic or neurotoxic 
conditions’ (Salvador-Carulla and Bertelli 2007). In case of 
genetic disorders, the chance to deﬁ  ne a phenotype is pro-
portional to the prevalence of the disorder and the research 
efforts on its phenomenology and pathophysiology. The 
same holds for emerging treatment modalities that will be 
increasingly targeted not at DSM diagnoses but at functional 
impairments crossing nosological boundaries (Verhoeven 
and Tuinier 2001; Green 2007).
The proposed bottom-up approach will be exempliﬁ  ed by a 
series of patients with psychiatric symptoms and genetic disor-
ders ranging from rather prevalent to rare. It will be advocated 
that the adequacy of the categorical taxonomy is inversely 
proportional to the amount of scientiﬁ  c information.
Examples of the bottom-up 
orientation
Fragile X syndromes
Fragile X syndrome (FXS) is the most common inherited 
cause of mental retardation with an overall prevalence of 1 in 
2000 to 1 in 3000 and originates from a trinucleotide repeat 
expansion of three bases (cytosine-guanine-guanine) in the 
fragile X mental retardation-1 gene (FRM1; Xq27.3) leading 
to hypermethylation and consequent silencing of the FMR1 
gene (Penagarikano et al 2007). A small expansion or pre-
mutation has approximately 55–200 repeats and occurs in 1 
in 700 females. The full mutation that has at least 200 repeats 
is associated with the syndrome. The premutation (70–200 
repeats) in males is associated with the fragile X-associated 
tremor/ataxia syndrome (FXTAS) and in females with a 
premature ovarian failure (POF). Recently, however, Adams 
and colleagues (2007) described that female carriers may 
also develop FXTAS. FXS, FXTAS, and POF are caused by 
a failure in the transcription of FRM1mRNA, either absent 
(FXS) or in excess (FXTAS and POF). The latter leads to a 
RNA toxic gain of function (Tassone et al 2007). The protein 
product FRMp which is absent in FXS and normal or low in 
the premutation is involved in synaptic function and structure 
(Jacquemont et al 2007). Overexpression of FRM1mRNA 
results in premature ovarian failure (Welt et al 2004; Lin 
and Yang 2006) and forms inclusions in neurons and glia 
cells in carriers that leads subsequently to cell damage and 
to a dementia syndrome characterized by ataxia and other 
neurological manifestations (Jacquemont et al 2004; Berry-
Kravis et al 2007).
Some structural abnormalities of the brain have been dem-
onstrated in FXS, especially an increased size of hippocampus, 
caudate, thalamus, and lateral ventricle whereas the cerebellar 
vermis is smaller (Moore et al 2004; Koukoui and Chaudhuri 
2007). FXTAS shows prominent white matter disease in the 
periventricular, subcortical, and mid-cerebellar peduncle as 
well as global brain atrophy (Adams et al 2007).
On the behavioral level, FXS is well known to be associ-
ated with irritability, hypotonia, mild motor delays, temper 
tantrums, and language delays during the ﬁ  rst years. In 
addition, autistic features, shyness, and social anxiety are 
frequently reported. The level of intellectual capacity var-
ies between 40 and 88, dependent on whether or not there 
is a complete or incomplete inactivation of the FRM1 gene. 
Affected females with a full mutation have a borderline to 
mild mental retardation. In a substantial number of patients 
with the full mutation, hyperactivity tends to improve dur-
ing adulthood. The most prominent psychiatric symptom in 
both males and females is anxiety, particularly social anxiety 
that is especially present in individuals without hyperactivity 
and irritability. In addition, obsessive compulsive symptoms 
are frequently observed that co-occur with perseverations or 
repetitive behaviors. Thus, the psychiatric phenotype of FXS 
comprises developmental delay, anxieties, autistic and obses-
sive compulsive features (Hagerman 2005). Female carriers 
of FXS are at risk for the development of affective symptoms 
and social anxiety (Franke et al 1998; Hageman et al 2007). 
The ‘social anxiety’ may look like, but is not adequately 
covered by the DSM-diagnosis of social phobia or social 
anxiety. The same holds for other symptomatology.
The neuropsychiatric proﬁ  le of FXTAS is dominated by 
deﬁ  cits in cognitive functioning associated with or preceded 
by symptoms of depression and anxiety as well as irritability 
and behavioural disinhibition, a symptom proﬁ  le that is usu-
ally seen in dementias. The full psychiatric proﬁ  le, however, 
has not been investigated as yet (Bacalman et al 2006).
Noonan syndrome
Noonan syndrome (NS) is an autosomal dominant geneti-
cally heterogeneous disorder with an estimated incidence of Biologics: Targets & Therapy 2008:2(3) 411
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1:1500 live births. The diagnosis of NS is primarily clinical 
and can be made by using a scoring system, listing major 
and minor congenital and morphological anomalies (Van 
der Burgt et al 1994). NS should be considered when typical 
facial dysmorphias are present as well as short stature, a 
variety of heart defects, particularly pulmonic stenosis and 
hypertrophic cardiomyopathy and skeletal deformations like 
pectus excavatum and carinatum. Additional features are 
cryptorchidism, lymphatic dysplasias, abnormal bleeding, 
and a lower level of IQ (Tartaglia and Gelb 2005).
Linkage analysis has demonstrated that the gene for NS 
is located on the distal part of chromosome 12q (Jamieson 
et al 1994). Subsequently, it was found that missense muta-
tions in the PTPN11 gene (12,q24.1) account for about half 
of NS patients (Tartaglia et al 2001). In addition, germline 
mutations in the KRAS gene were reported in a minority 
of patients with severe forms of NS (Schubbert et al 2006). 
Recently, a novel mutation in another gene involved in the 
RAS-MAPK pathway was discovered in a subset of patients 
with NS, the SOS1 gene (Roberts et al 2006). Mutations in 
the PTPN11 gene result in expression of a SHP-2 protein with 
an increased phosphatase activity that may lead to aberrant 
neural cell-fate decisions during development which may 
be implicated in cognitive impairments in NS (Gauthier 
et al 2007).
Data about the psychological and psychiatric charac-
teristics of NS patients are scarce. In about one-third of 
patients a mild mental retardation is found. In most patients, 
however, the level of intelligence falls within the normal 
range (Allanson 2005). Mood disturbances as well as social, 
communication, and planning problems have been found in 
children with NS (Wood et al 1995; Van der Burgt et al 1999; 
Sarimski 2000; Lee et al 2005).
Given the prevalence of NS, it is remarkable that virtually 
no reports have been published about classical psychiatric 
syndromes and that hardly any information is available about 
the cognitive and mental health status of adult patients with 
NS. Recently, Verhoeven and colleagues (2008) reported 
on a group of 10 adult NS patients not referred for psychi-
atric or behavioral problems. Apart from a variable level 
of intelligence, there was a moderately impaired social 
cognition in terms of emotion recognition and alexithymia. 
In some patients mild signs of anxiety and lowered mood 
were observed that, however, did not meet the criteria for a 
speciﬁ  c psychiatric disorder.
Interestingly, the neuropsychiatric proﬁ  le of NS com-
prises subtle deﬁ  cits in social and emotional recognition 
while, given the developmental problems associated with 
the somatic comorbidity, much more psychiatric morbidity 
would be expected. It can be hypothesized that NS ‘protects’ 
against the development of major psychiatric illnesses.
22q11 deletion syndrome
This syndrome (22q11DS), previously termed velo-cardio-
facial syndrome, is a common genetic disorder estimated 
to affect 1 in 4000 individuals and is associated with a 
deletion of varying size on the long arm of chromosome 22 
(22q11.2). Several genes that are involved in the deletion 
have been investigated of which that coding for catechol-
o-methyl transferase (COMT) and the TBX1 gene are the 
best known. Some evidence is available that polymorphism 
for the COMT gene is associated with differences in brain 
anatomy (Van Amelsfoort et al 2008). Magnetic resonance 
imaging has demonstrated wide spread deﬁ  cits in white mat-
ter and reduced brain volumes (Van Amelsfoort et al 2004; 
Schaer et al 2006). Polymicrogyria, however, is reported 
most frequently (Robin et al 2006).
In addition, COMT has been demonstrated to be associ-
ated with cognitive deﬁ  cits, irrespective of diagnosis (Akil 
et al 2003; Diamond 2007). Since the gene for COMT, an 
enzyme involved in the degradation of dopamine, is located 
in the commonly deleted region in patients with 22q11 dele-
tion syndrome, Karayiorgou and colleagues (1998) initially 
suggested an association between schizophrenia and a low 
activity allele of COMT. This observation could, however, 
not be replicated in 22q11DS patients with psychotic disor-
ders (Murphy et al 1999) nor in patients with schizophrenia 
(Arinami et al 2001; De Chaldée et al 2001; Glaser et al 2006; 
Williams et al 2007).
With respect to the TBX1 gene, several lines of evidence 
support the hypothesis that it is involved in the vascular 
perfusion of the embryonic brain (Robin et al 2006). It has 
been demonstrated that haploinsufﬁ  ciency of TBX1 results 
in a spectrum of distinct vascular and heart defects (Vitelli 
et al 2002). TBX1 variations in psychiatric populations most 
probably do not contribute to major psychiatric disorders 
(Funke et al 2007).
The clinical phenotype of 22q11DS is characterized by a 
variable degree of intellectual disability, cardiac anomalies, 
pharyngeal hypotonia and cleft palate, abnormal facies, 
thymic hypoplasia, and hypocalcaemia due to hypopara-
thyroidism (Shprintzen 2000). The behavioral phenotype in 
childhood and adolescence comprises social withdrawal, a 
special attachment to mother or other caregivers, poor social 
skills, emotional instability, affective problems, anxieties, 
diminished ﬂ  exibility, and attention deﬁ  cits (Swillen et al Biologics: Targets & Therapy 2008:2(3) 412
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1999; Antshel et al 2007; Majerus et al 2007). In adults with 
22q11DS, a discrepancy between verbal and performal IQ 
as well as an impaired visuoperceptual ability and a dimin-
ished comprehension of abstract and symbolic language has 
been found (Henry et al 2002; Verhoeven et al 2007). In 
terms of personality constructs most patients score high on 
neuroticism and low on agreeableness, a proﬁ  le associated 
with adjectives like shy, moody, irrational, and unempathetic 
(Verhoeven et al 2007).
In patients after adolescence a high prevalence of several 
psychiatric illnesses is reported including bipolar (spectrum) 
disorder, anxiety disorder, obsessive compulsive disorder, 
autism spectrum disorders and psychotic disorders, espe-
cially schizophrenia (Shprintzen et al 1992; Papoulos et al 
1996; Murphy et al 1999; Vogels et al 2002; Jolin et al 
2006; Vorstman et al 2006). It should be stressed, however, 
that the psychotic symptoms are totally different from that 
described in the DSM-schizophrenia category (Sphrintzen 
2000; Verhoeven et al 2007). ‘Going up’ from the microde-
letion to the psychiatric symptom proﬁ  le does not lead to a 
diagnosis of schizophrenia unless a narrow-minded clinical 
observation is used. Following the reverse trajectory, going 
from schizophrenia to a 22q11DS, no association has been 
demonstrated. Several large-scale studies in patients with 
schizophrenia have shown a prevalence of 22q11 deletion 
syndrome of less than 1% (Sugama et al 1999; Arinami et al 
2001; Ivanov et al 2003; Horowitz et al 2005; Hoogendoorn 
et al 2008). Genome-wide genetic linkage in patients with 
schizophrenia did not conﬁ  rm a linkage with 22q11 (Shaw 
et al 1998; Faraone et al 1998; Kaufmann et al 1998; Gurling 
et al 2001; Hamshere et al 2005; Fanous et al 2007).
Prader-Willi syndrome
Prader-Willi Syndrome (PWS) is a multisystem disorder 
with an estimated prevalence of 1:10.000–15.0000 and is 
accompanied by a variable degree of intellectual impair-
ment. The syndrome arises from the lack of expression of 
genes on the paternally derived chromosome 15q11-13 as a 
result of a paternal deletion (75%), an uniparental maternal 
disomy (UPD; 20%), or other chromosomal anomalies. All 
lead to the loss of expression of a group of genes on 15q11-
13 that are only expressed from the paternally inherited 
chromosome because the maternal contribution is silenced. 
The function of several imprinted genes in this region is 
unknown (Cassidy and McCandless 2005). One of the 
imprinted genes is NECDIN that is thought to be related 
to respiratory disturbances in PWS (Zanella et al 2008). 
Since the γ-aminobutyric acid (GABA) receptor subunit 
genes in this region are all nonimprinted, their expression 
is increased in cases with UPD and decreased in those with 
a deletion (Bittel et al 2003). Support for an involvement 
of GABA-receptor genes in the phenotype was presented 
by Ebert and colleagues (1997) who found elevated plasma 
levels of GABA in PWS patients irrespective of the genetic 
etiology. This observation was interpreted as a compensa-
tory mechanism in response to hyposensitivity of a subset 
of GABA receptors. Later, a PET-scan study demonstrated 
a reduced number of GABAA receptors in one speciﬁ  c brain 
area of PWS patients (Lucignani et al 2004).
With respect to the genes involved in the expression of 
the PWS genotype, it has recently be shown that, apart from 
the nonexpression of paternally expressed genes from the 
15q11-13 region, PWS differs enormously from controls 
in the expression of genes located on other chromosomes 
of which several are implicated in neurodevelopment and 
function (Bittel et al 2007).
Since many of the features of PWS are suggestive for a 
hypothalamic/pituitary dysfunction, both postmortem and 
neuroimaging studies have been performed. Swaab and col-
leagues (1995) found a signiﬁ  cantly lower number of small 
oxytocin secreting neurons in the paraventricular hypothala-
mus and, in some cases, a reduction of vasopressin secreting 
neurons as well as a diminished vasopressin precursor pro-
cessing. MRI-studies have shown a reduction in the pituitary 
height suggestive for alterations on the hypothalamic-pituitary 
level (Iughetti et al 2008) as well as structural brain anomalies 
such as enlarged ventricles (Miller et al 2006).
The clinical manifestations of PWS are: reduced fetal 
activity during pregnancy, a transient severe hypotonia and 
feeding problems in the neonatal period, a variable degree 
of intellectual disability, delayed developmental milestones, 
hyperphagia, obsessive-compulsive features like skin pick-
ing, controlling behaviors and repetitive question asking, 
temper tantrums, stubbornness, and a variety of hypothalamic 
dysfunctions. The latter become manifest as hypogonadism, 
short stature, sleep disturbances and defects in temperature 
regulation (Cassidy and Candless 2005).
Patients with UPD have been demonstrated to differ 
from those with a deletion with respect to physical, cogni-
tive, and behavioral parameters. Moreover, a larger deletion 
is associated with more obsessive compulsive behaviors, 
poorer adaptive behavior and cognitive dysfunction (Bittel 
et al 2006).
With respect to the psychopathology in patients with 
PWS, a broad array of disorders with a prevalence up to one 
third of the patients is described that ranges from (atypical) Biologics: Targets & Therapy 2008:2(3) 413
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psychotic and bipolar affective disorder (Verhoeven et al 
1998, 2003a; Verhoeven and Tuinier 2006; Soni et al 2007) to 
obsessive compulsive disorder (Clarke et al 2002), attention-
deﬁ  cit/hyperactivity disorder (Wigren and Hansen 2005) 
and pervasive developmental disorder (Descheemaecker 
et al 2006). Concerning psychotic disorders, an association 
has been demonstrated with UPD (Boer et al 2002; Vogels 
et al 2003; Verhoeven et al 2003a, 2003b). Since the gene 
for the α5 subunit receptor is located in the 15q11-13 region, 
it was hypothesized that GABA-ergic neurotransmission 
may be involved in the pathophysiology of bipolar illness 
in general because of the high prevalence of this disorder in 
PWS (Ewald et al 1994).
As in the 22q11 deletion syndrome, the ‘bottom-up’ 
approach, form the genetic defect to the psychiatric symp-
tom proﬁ  le, does not lead to a simple categorical psychiat-
ric classiﬁ  cation but to the description of a syndrome that 
encompasses developmental contingencies from the prenatal 
period, hypothalamic dysfunctions and a certain probability 
of behavioral disturbances and psychiatric symptoms, the so 
called Prader-Willi neuropsychiatric phenotype.
Rare genetic disorders
In contrast to the above mentioned genetic syndromes with 
their well described behavioral phenotypes, the psychiatrist 
may encounter other genetic disorders. The search for such 
disorders is indicated if cognitive functions are compromised 
and a developmental delay or dysmorphias are present. Four 
patients will be described who were referred for neuropsychiat-
ric evaluation because of psychotic or depressive symptoms.
Case 1
Case 1 is a 57-year-old male who had been treated from his 
twenties with several antidepressants and mood stabilizers 
for mood disturbances. His somatic history showed 
diabetes mellitus type 2 with neuropathy, mild hyperten-
sion, and loss of libido and erectile dysfunction. The family 
history was void of mental disorders, congenital anomalies, 
and neuropsychiatric disorders. Neuropsychiatric evaluation 
revealed lowered mood, fatigue, hypersomnia, and apathy. 
His total IQ was 128. There were no relevant somatic abnor-
malities apart from central obesity (weight: 115 kg; BMI 35) 
and infertility due to azoospermia. Laboratory investigation 
showed a low level of testosterone (4.6 nmol/l; normal range 
9–18 nmol/l) and increased levels of luteinizing hormone and 
follicle-stimulating hormone. Because of the combination of 
infertility and testosterone deﬁ  ciency, cytogenetic analysis 
was performed that revealed a Robertsonian translocation 13; 
14 (karyotype: 45,XY der(13; 14)(q10; q10). This autosomal 
aberration is the most frequent chromosomal abnormality 
demonstrated in male infertility (Tuerlings et al 1998). A 
diagnosis of atypical depression due to testosterone deﬁ  -
ciency was made and all psychotropics were tapered off. 
Subsequently the patient became less apathetic and his mood 
level normalized. He was referred to the endocrinologist for 
treatment with testosterone.
Although lower testosterone levels are frequently seen in 
patients with type 2 diabetes (Kapoor et al 2007), it is possible 
that in this patient the etiology of both infertility and low 
testosterone as well as his long lasting atypical mood disorder 
is of chromosomal origin, although no health problems are 
described in this translocation.
Case 2
Case 2 is a 24-year-old female with moderate mental retarda-
tion whose history is characterized by a developmental delay. 
Her family history did not reveal any abnormalities. At the 
age of 14 she developed recurrent episodes with anxiety, 
irritability, mood instability, perceptual disturbances, and 
challenging behaviors. A diagnosis of psychotic disorder 
with comorbid atypical autism was made and the patient was 
treated with antipsychotics. At neuropsychiatric examination, 
no dysmorphias were observed. She complained about severe 
anxieties and extreme responses to environmental stimuli 
and chaotic behaviour. Her total IQ was 48. All laboratory 
parameters were normal. Cytogenetic analysis revealed a 
partial duplication of chromosome 13 [(13)(q14.1q21.3)]. 
Treatment with antipsychotics was discontinued and an 
adaption of the environmental contingencies resulted in a 
clear amelioration of her general functioning.
In this patient a previously undescribed chromosomal 
abnormality was found that was considered to explain the 
moderate mental retardation as well as the vulnerability to 
develop anxiety symptoms.
Case 3
Case 3 was hospitalized for the ﬁ  rst time at the age of 81 
because of disorientation, self neglect, and paranoid ideation. 
Her history showed long-lasting social incompetence, para-
noid attitude, and social isolation. No formal psychiatric diag-
nosis was ever made. Neuropsychiatric evaluation disclosed 
symptoms of a major depression with psychotic features and 
autistic behavior. Her IQ was 82. Genetic analysis showed a 
balanced translocation between the short arm of chromosome 
X and the long arm of chromosome 19 [46,X,t(X; 19)(p11.4; 
q13.3)] (Verhoeven et al 2007).Biologics: Targets & Therapy 2008:2(3) 414
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In this older patient the genetic disorder may be 
responsible for the low level of intellectual function and the 
disordered communication.
Case 4
Case 4 is a 31-year-old female who was referred for recurrent 
short-lasting psychotic episodes for which she had been 
treated with antipsychotics for several years. Her history 
demonstrated developmental delay, poor social skills, and 
learning difﬁ  culties. At the age of 10, an autistiform disor-
der was considered. There was no family history of mental 
retardation or mental illness. Neuropsychiatric evaluation 
revealed minor dysmorphias and a lack of social reciproc-
ity, verbal perseverations, paranoid attitude, anxiety, mood 
instability and irritability. Her total IQ was 68. Chromosome 
analysis demonstrated a translocation between chromo-
somes 2 and 10 (46,XX,t(2; 10)(p23; 22.1). Treatment with 
risperidone and valproic acid resulted in a stabilization of 
mood and disappearance of psychotic symptoms over sev-
eral years (Verhoeven et al 2006). The social incompetence 
remained.
As in the other patients, an undescribed translocation was 
found that may probably explain the mild mental retardation 
and the psychiatric symptoms.
Discussion
From the presented examples it becomes clear that in case 
of rather prevalent genetic syndromes, a phenotype can be 
outlined. This means that the chance to present somatic or 
behavioral sign and symptoms is increased compared with the 
normal population. There is no linear relationship between 
genes and phenotype because phenotypic variability is the 
rule (Sheldon and Turk 2000; Gropman and Adams 2007). 
The concept of a behavioral phenotype should comprise 
not only behavioral elements and psychiatric symptoms 
but also physical features (Turk and Hill 1995) since all are 
expressions of the genotype modiﬁ  ed by environmental and 
epigenetic factors. Furthermore, it should be noticed that 
neurocognitive development can be inﬂ  uenced by an initial 
deﬁ  cit resulting in a phenotypic amalgam of the deﬁ  cit and its 
developmental consequences (Cornish et al 2004). This phe-
nomenon is analogue to that of trait ampliﬁ  cation as described 
for borderline personality disorders by Paris (1994).
When the phenotype is restricted to psychiatric disorders, 
any speciﬁ  city for a genetic disorder is absent since psy-
chotic symptoms as well as mood and anxiety disorders are 
described in a great variety of different genetic syndromes 
(Bassett et al 2000; Verhoeven et al 2004). Examples are 
PWS and 22q11DS in which a great variety of psychiatric 
syndromes can be found that do not give any clue to the 
existence of a speciﬁ  c genetic etiology. If one adds, however, 
neonatal hypotonia, skin picking and hyperphagia or nasal 
speech, conotruncal heart malformations and cleft palate, 
then the identiﬁ  cation of the syndrome is rather easy.
In almost all syndromes described above, autism or 
autistic-like features may be present. Such features must 
always lead to a neurogenetic investigation because of the 
high prevalence of identiﬁ  able medical conditions (Bradley 
Schaefer and Lutz 2006). The concept of autism as advanced 
by Gillberg (1992) may be of heuristic value since it acknowl-
edges that autism is a behavioral syndrome shading into 
several other disorders. This behavioral syndrome can be 
caused by a variety of medical conditions and each of these 
conditions represents a separate disease entity (Gillberg 1992; 
Gillberg and Billstedt 2000).
Following the bottom-up approach, the analysis of the 
complex interplay between biological and contextual systems 
may eventually lead to a true functional classiﬁ  cation of men-
tal disorders. The search for candidate genes for psychiatric 
disorders has given great impetus for this endeavor. A good 
example is the discovery of the DICS1 gene in one family that 
was originally thought to be causally related to schizophrenia 
(St. Clair et al 1990). Later a biochemical cascade became 
clear with consequences for neurodevelopment and function 
that predispose for psychiatric symptoms across diagnoses 
(Blackwood et al 2007; Millar et al 2007).
The phrentic adherence of psychiatry to etiologically 
neutral prototypical behavioral syndromes, categorical 
diagnoses, severely hampers the cross talk with biological 
research. It should be realized that a gene defect does not 
code for a categorical psychiatric disorder but for a biologi-
cal dysfunction that has a certain probability to be associ-
ated with a range of psychiatric symptoms. As stated by 
Kendler (2005) ‘the appropriate level of explanation for gene 
action is much more likely to be basic biological or mental 
processes that contribute to psychiatric disorders rather than 
the disorders themselves’.
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